Eeson Rajendra

8PUBLICATIONS

87CO-AUTHORS

Molecular targetsCheminformatics and quantitative structure-activity relationshipsCell development, proliferation and deathRadiation therapyCharacterisation of biological macromolecules

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 12, 2026

<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

|Dec 08, 2025

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Eeson Rajendra, Claudio A Lademann, Bethany Mason

|Dec 08, 2025

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Sam E Mann, Owen A Davis, Jörg Bomke

|Sep 17, 2025

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Sam E Mann, Julien Lefranc, Omar Alkhatib

|Feb 28, 2024

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Patrick G Pilié, Virginia Giuliani, Wei-Lien Wang

|Dec 18, 2023

Quantitative, titratable and high-throughput reporter assays to measure DNA double strand break repair activity in cells.

Eeson Rajendra, Diego Grande, Bethany Mason

Pageof 2

Frequent Collaborators

Robert A Heald

Graeme C M Smith

Helen M R Robinson

Diego Grande

Claire McWhirter

Alessandro Galbiati

Marie Laure Boursier

Jayesh Majithiya

Marco Ranzani

Vera Grinkevich

Frequent Collaborators

Robert A Heald

Graeme C M Smith

Helen M R Robinson

Diego Grande